News
Public · Published
Buy Max Healthcare; target of Rs 1160: Choice Institutional Equities
Choice Institutional Equities changed its rating on Max Healthcare from ADD to BUY after a stock correction, while retaining its target price of INR 1,160. The report cites expansion plans, improving use of new beds and growth in international healthcare, diagnostics and homecare.
Published:
Updated:
What happened
Choice Institutional Equities changed its rating on Max Healthcare from ADD to BUY after a stock correction, while retaining its target price of INR 1,160. The report cites expansion plans, improving use of new beds and growth in international healthcare, diagnostics and homecare.
Confirmed
Global impact / market context
The recommendation rests on the expectation that new hospitals and beds will attract more patients as they mature, while diagnostics and homecare add revenue streams. If those plans deliver, higher facility use could spread operating costs across more activity and support earnings growth.
Analyst inference
Choice forecasts revenue, EBITDA and adjusted profit after tax to grow at compound annual rates of 23.7%, 26.8% and 24.0% over FY26–29E. It also reduced its hospital valuation multiple from 26x to 24x EV/EBITDA, a measure comparing company value with operating earnings.
Confirmed
What to watch
- Check whether new beds are filled steadily as facilities mature; stronger utilisation, meaning a higher share of beds in use, would support the report’s forecast that operating leverage can lift earnings. Analyst inference
- Track progress on brownfield and greenfield expansion, meaning additions at existing sites and construction of new facilities, and whether these investments expand capacity as planned. Analyst inference
- Watch for continued growth in international healthcare, diagnostics and homecare, which the report identifies as sources of revenue diversification and longer-term earnings growth. Analyst inference
Evidence
- Original source link unavailable